Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryAngiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertensionInformative noncompliance in endpoint trialsCommunication in the heart: the role of the innate immune system in coordinating cellular responses to ischemic injuryStage B: what is the evidence for treatment of asymptomatic left ventricular dysfunction?Cardiac biomarkers: new tools for heart failure managementFemale-specific aspects in the pharmacotherapy of chronic cardiovascular diseasesRole of angiotensin II in cardiovascular disease therapeutic implications of more than a century of researchPharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonistIncreased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failureNovel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.Renin-angiotensin system blockade for the risk of cancer and death.Why not prescribe the best drugs for hypertension now?Comparing angiotensin II receptor blockers on benefits beyond blood pressureRAAS inhibitors and cardiovascular protection in large scale trials.A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitorsNonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Issues in regulatory guidelines for data monitoring committees.Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial.Dual blockade of the renin-angiotensin system in diabetic nephropathy.Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors: challenges in comparative effectiveness using Medicare data.Facts and principles learned at the 31st Annual Williamsburg Conference on Heart Disease.Arterial stiffness and cardiovascular therapyAngiotensin receptor blockers and risk of myocardial infarction: systematic review.The past, present and future of renin-angiotensin aldosterone system inhibitionRenin-angiotensin-aldosterone system blockade for cardiovascular diseases: current statusThe homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure.Evaluation of Cardiac Function by Transthoracic Echocardiography in Subjects with ST-Segment Elevation Myocardial Infarction Following Primary Percutaneous Coronary Intervention according to Valsartan Dose: The Valsartan One Center Trial.Ace revisited: a new target for structure-based drug design.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyCardio classics revisited--focus on the role of candesartan.A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failureClinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study.Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with theThe therapeutic role of RAS blockade in chronic heart failure.Ongoing trials involving angiotensin-converting enzyme inhibitors.The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.
P2860
Q22241786-3FAAD280-9633-4A87-84AB-956290EEA87EQ24194304-E3E61840-7816-432B-AF6C-CB2943AD95A4Q24791524-D3FC4AFC-A349-41D8-83FB-D5ACFEADB2DBQ26830128-818A13C7-AF4B-44E3-B56A-BBB0D80D0496Q26853063-867A2429-8280-4A2F-839A-BFE054FC042DQ26991726-2322A9AC-AF6A-459D-BD8D-E38F3381E123Q28182631-DC8FF56D-1412-47E9-BEF5-ACBC505FEBA5Q28272171-EE38406E-4EEA-4D3F-BE04-ED04250491C3Q28282619-A5BB450C-9E86-4B0B-B609-FDFCD93E08AAQ28575465-846368CB-D4CD-4451-B636-B0C620DB082CQ30235583-221120A9-559B-4A33-9476-FDD2EB63EB44Q30249043-DE641563-5C14-4D5B-B4BD-19ABCC71AA22Q30333019-C3B32BD9-DC0D-455A-9FDA-10912D876494Q30360678-F6295F9B-66D6-441E-8333-C2716CD6F85BQ30424541-3F35F9AA-506F-40E0-9BDE-15FBFF75C70CQ30432209-D4B0F228-6267-4DAB-BA09-D6F725EEE200Q30583012-B7C4D1E9-CACE-48A3-94EA-25E3013F4E95Q33226975-33C9624F-D747-4A6C-AFE4-1FDD206483E1Q33403831-28688ABF-7DC8-40FF-970A-6E6F38DB5C36Q33433326-6CFC03C2-E745-4CED-968A-790AD8259863Q33610694-2097F3E5-FC28-4A0A-A3AB-87481E55D15EQ33803829-F8A85E2C-56C4-4035-9EDD-0CDF432199E7Q33858023-F3EB008E-F3BD-46C3-87ED-1F0C45465623Q33944878-A7638DBE-C8BE-4692-9680-88F90565E773Q34079790-65324C8A-D0A6-49A4-9A37-96FE070C212FQ34081519-AC8B1AB5-80DB-4A36-90E1-5C1E240A1C1DQ34094354-2B744CEB-BA7D-41E5-876D-E082E25BD729Q34124779-89284737-BA74-4F5D-9816-0DF8BF76155FQ34200352-9F092592-1831-4536-9B7A-945E86E9DFD4Q34201349-56E30E82-EBB0-4A6D-A4C7-F9F3B5CE27EFQ34282839-1531CBC1-8615-43D8-9941-E6897C687E49Q34386587-3FE40738-BF5F-47B0-9D05-FE20EAABCDB8Q34417462-64BBF57E-841A-48A0-AD3A-1ABF0BAFE37EQ34449030-2792AB6B-0FC0-488A-8334-07A8E20C5122Q34565386-B0545FD6-A2A7-472B-8140-2184393EB101Q34614447-1AEE27D1-CD5F-48C0-9CC2-4DEF96DAAD8EQ34830023-A06F335D-EC8A-47AE-A675-6670C0B8B280Q34915602-1408CFC4-608F-4BEA-816A-F436095ECB36Q35001043-D0AFCE5E-EA2F-4CA6-88BB-5E8F093C062CQ35001942-F46810AC-2492-4AD6-9EC7-FCBD41629656
P2860
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@ast
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@en
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@nl
type
label
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@ast
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@en
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@nl
prefLabel
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@ast
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@en
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@nl
P1433
P1476
Effects of losartan and captop ...... tensin II Antagonist Losartan.
@en
P2093
OPTIMAAL Steering Committee of the OPTIMAAL Study Group
P304
P356
10.1016/S0140-6736(02)09895-1
P407
P577
2002-09-01T00:00:00Z